美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

三倍做多标普生物-Direxion

166.47

+17.4311.69%

盘后：165.60-0.8704-0.52%19:59 EST

成交量：51.46万

成交额：8,348.16万

市值：5.78亿

市盈率：- -

高：168.04

开：157.98

低：156.69

收：149.04

52周最高：198.18

52周最低：32.55

股本：347.45万

流通股本：347.45万

量比：0.77

换手率：14.81%

股息：1.34

股息率：0.81%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

山西山阴生物科技公司爆炸已致8人遇难，涉事企业法人代表已被控制

校企合作结硕果

2026年度南昌市灵活就业人员缴纳医保指南出炉

一批制造公众用药焦虑，引导购买高端医疗保险的账号被依法处置

山东新华制药股份(00719)终止收购挪亚圣诺(太仓)生物科技有限公司股权

长春高新：聚焦生物医药主业、深化创新驱动

【券商聚焦】中信证券：商保有望成为医疗健康产业支付端的核心增量

成大生物（688739）披露拟参与设立5.02亿元生物医药产业投资基金，2月5日股价上涨0.39%

医疗保健板块动态：市场焦点解读

Viemed Healthcare, Inc.盘中异动股价大涨5.19%报8.52美元

爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议

Healthcare Triangle, Inc.盘中异动跌6.40% 换手率达47.93%

瑞银——美国医疗保健服务行业周度观察（附下载）

外资精华观点

AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元核心哮喘疗法已进入III期临床

智通财经网

诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心

生物科技公司PrimeGen将通过15亿美元SPAC交易上市

环球市场播报

复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务

一线｜脑机接口商业化转向：企业正加速从消费场景转向医疗健康领域

红日药业：公司业务布局可大致分为中药配方颗粒、成品药、医疗器械、原辅料、医疗健康服务和药械智慧供应链

创新链产业链无缝对接推动产业整体跃升

无锡新传媒

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/LABU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多标普生物-Direxion","latestPrice":166.47,"timestamp":1770411600000,"preClose":149.04,"halted":0,"volume":514622,"hourTrading":{"tag":"盘后","latestPrice":165.5996,"preClose":166.47,"latestTime":"19:59 EST","volume":2147,"amount":355810.367,"timestamp":1770425990968,"change":-0.8704,"changeRate":-0.005229,"amplitude":0.006187},"delay":0,"changeRate":0.11694847020933982,"floatShares":3474486,"shares":3474486,"eps":0,"marketStatus":"休市中","change":17.43,"latestTime":"02-06 16:00:00 EST","open":157.98,"high":168.0401,"low":156.689,"amount":83481646.33569999,"amplitude":0.076161,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":149.04,"sharesOutstanding":3424486,"nav":166.894,"aum":571525356.97,"dividendRate":0.008058,"bidAskSpread":0.001871,"preHourTrading":{"tag":"盘前","latestPrice":155.83,"preClose":149.04,"latestTime":"09:25 EST","volume":11314,"amount":1745765.81332,"timestamp":1770387916532,"change":6.79,"changeRate":0.045558,"amplitude":0.024826},"postHourTrading":{"tag":"盘后","latestPrice":165.5996,"preClose":166.47,"latestTime":"19:59 EST","volume":2147,"amount":355810.367,"timestamp":1770425990968,"change":-0.8704,"changeRate":-0.005229,"amplitude":0.006187},"volumeRatio":0.7650218554198999,"impliedVol":0.979,"impliedVolPercentile":0.7769},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3474486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7650218554198999,"shares":3474486,"dividePrice":1.3414,"high":168.0401,"amplitude":0.076161,"preClose":149.04,"low":156.689,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":166.47,"eps":0,"divideRate":0.008058,"volume":514622,"delay":0,"ttmEps":0,"open":157.98,"prevYearClose":159.39,"prevWeekClose":165.86,"prevMonthClose":165.86,"prevQuarterClose":159.39,"fiveDayClose":165.86,"twentyDayClose":164.43,"sixtyDayClose":121.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609522115","title":"山西山阴生物科技公司爆炸已致8人遇难，涉事企业法人代表已被控制","url":"https://stock-news.laohu8.com/highlight/detail?id=2609522115","media":"新京报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609522115?lang=zh_cn&edition=fundamental","pubTime":"2026-02-08 10:03","pubTimestamp":1770516180,"startTime":"0","endTime":"0","summary":"据新华社太原2月8日电 记者8日9时30分左右从山西省朔州市山阴县佳鹏生物科技有限公司“2·07”事故现场指挥部了解到，2月7日凌晨在山阴县佳鹏生物科技有限公司发生的爆炸已造成8人遇难。目前，涉事企业法人代表已被控制，朔州市已经成立事故调查组。事发企业位于距离山阴县城40余公里的一处山洼中，记者在事故现场看到，事发地有暗黄色烟雾散出，现场处置工作仍在进行。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-02-08/doc-inhmaism3364455.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-08/doc-inhmaism3364455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","159837","BK4585","BK4588"],"gpt_icon":0},{"id":"2609521384","title":"校企合作结硕果","url":"https://stock-news.laohu8.com/highlight/detail?id=2609521384","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609521384?lang=zh_cn&edition=fundamental","pubTime":"2026-02-08 05:51","pubTimestamp":1770501060,"startTime":"0","endTime":"0","summary":"（来源：辽宁日报）转自：辽宁日报 春节将至，位于朝阳市朝阳县农产品加工园区的朝阳八方生物科技有限公司仍一片繁忙，生产线高速运转，员工加紧进行虾青素相关产品的检测工作。朝阳八方生物科技有限公司与辽宁省微生物科学研究院、朝阳师范学院、辽宁大学等高校和科研院所建立了紧密的技术合作关系，成功突破高含量虾青素鸡蛋生产等关键技术，形成一套成熟的功能性农产品生产体系，已成功跻身高新技术企业、雏鹰企业行列。 图为朝阳八方生物科技有限公司员工在微生物发酵车间工作。 张书宁 本报特约记者 仇一军 摄 \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-08/doc-inhkzxat0681931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU"],"gpt_icon":0},{"id":"2609254915","title":"2026年度南昌市灵活就业人员缴纳医保指南出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2609254915","media":"南昌发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609254915?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 14:30","pubTimestamp":1770445800,"startTime":"0","endTime":"0","summary":"灵活就业人员自愿参加职工医保的，应当按年一次性缴纳全年费用，不允许按月缴费，待遇享受按有关规定执行。职工医保停保后转为以灵活就业人员身份参保的，可从停保次月一次性缴费至当年的12月31日。当年已参加居民医保并缴费的，不得中途再以灵活就业人员身份参加当年职工医保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-02-07/doc-inhkykzi4247953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","XBI","BK4588","XLV","BK4585","LABU"],"gpt_icon":0},{"id":"2609459639","title":"一批制造公众用药焦虑，引导购买高端医疗保险的账号被依法处置","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459639","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459639?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 20:23","pubTimestamp":1770380580,"startTime":"0","endTime":"0","summary":"来源：北京商报\n　　2月6日，北京商报记者了解到，近期，中央网信办会同国家医保局深入整治涉医药集中带量采购的网上虚假不实信息，依法依约处置一批污名集采、制造焦虑、误导公众的账号。根据通报的典型案例，微博账号“成都XXX”，抖音账号“琼波XX”“亮晶晶的XX”等，歪曲国家政策，编造“进口药集体退出中国”等不实信息，煽动网民对原研药与仿制药的对立情绪，其中部分账号旨在制造公众用药焦虑，引导公众购买相关保健品、高端医疗保险，或诱导公众到特定的互联网平台购药。涉及的账号已被依法依约采取处置措施。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：曹睿潼","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-06/doc-inhkwssf2096736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","XBI","BK4581","BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2609569452","title":"山东新华制药股份(00719)终止收购挪亚圣诺(太仓)生物科技有限公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2609569452","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609569452?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 17:50","pubTimestamp":1770371401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)发布公告，有关本公司与挪亚圣诺(欧洲)公司签署《股权收购意向协议》。股权收购意向协议仅系各方经友好协商达成的初步意向，然而，经进一步讨论及磋商后，订约方未能就正式协议的条款及条件达成共识。本公司因此并无就该项目订立正式协议，该项目亦不会进行。故此，本公司已决定终止该等股权收购意向协议。终止《股权收购意向协议》系本公司审慎研究后作出的决定，不会影响本公司现有生产经营活动，也不会对本公司的发展造成不利影响，不存在损害本公司及全体股东，特别是中小股东利益的情形。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402599.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK4588","00719","BK1191","BK4585","159837","LABU"],"gpt_icon":0},{"id":"2609563345","title":"长春高新：聚焦生物医药主业、深化创新驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2609563345","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609563345?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 16:24","pubTimestamp":1770366259,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：安科生物无论是产品能力还是盈利能力都已经远超公司十倍不止,请问公司管理层如何看待这一翻转？长春高新回复：感谢您对公司的关注。公司目前虽然因为新品布局、全球化拓展带来短期投入加大，阶段性影响净利润，但管理层始终希望可以通过聚焦生物医药主业、深化创新驱动，持续提升公司核心竞争力，最终实现高质量稳健发展，谢谢！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260206/32003747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LABU","BK0075","000661","BK0188","161726","399441","BK0057","BK0028","BK4585","BK0239","BK0046","BK4588"],"gpt_icon":0},{"id":"2609536060","title":"【券商聚焦】中信证券：商保有望成为医疗健康产业支付端的核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2609536060","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609536060?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 08:31","pubTimestamp":1770337883,"startTime":"0","endTime":"0","summary":"下一阶段，该机构认为商保综合服务提供商有望解决保司端人才、数据制约，打开创新药械企业创新价值兑现面临的结构性瓶颈，进一步助推商业健康险行业边际加速发展。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/NGZhNmEwMzJkNDhkNWE0NjE0NjM0MTA4NTA5NzI5NDQz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974659","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","LU1328615791.USD","BK1516","06030","LU1064131003.USD","LU2495084118.USD","LU2289578879.USD","XBI","LU1997245177.USD","BK4588","LU1255011170.USD","BK4581","LU1064130708.USD","BK0276","BK0012","LU0405327148.USD","BK0183","LU1997245094.SGD","LU0405327494.USD","BK4585","LU1720050803.USD","XLV","LABU","600030","LU1655091616.SGD","BK1521","159760","BK1564","BK0188","BK0196","LU2148510915.USD","LU1997244956.HKD","LU1794554557.SGD","BK0028"],"gpt_icon":0},{"id":"2609191535","title":"成大生物（688739）披露拟参与设立5.02亿元生物医药产业投资基金，2月5日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609191535","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609191535?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 08:04","pubTimestamp":1770336249,"startTime":"0","endTime":"0","summary":"近日，辽宁成大生物股份有限公司披露《2026年第一次临时股东会会议资料》。公告显示，公司拟与控股股东辽宁成大及其全资子公司共同发起设立成大生物医药产业投资基金，基金设立规模为50,200万元，公司作为有限合伙人认缴出资4亿元。本次事项构成关联交易，需提交股东大会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260206/32002619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688739","399441","LABU","BK4588","161726","BK0239","BK4585"],"gpt_icon":0},{"id":"1125439079","title":"医疗保健板块动态：市场焦点解读","url":"https://stock-news.laohu8.com/highlight/detail?id=1125439079","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125439079?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 05:52","pubTimestamp":1770328365,"startTime":"0","endTime":"0","summary":"最新一期医疗保健板块市场动态分析。Neuren公司表示，其合作伙伴Acadia Pharmaceuticals近期收到欧洲药品管理局关键委员会的通报，trofinetide的上市许可申请未获支持票。杰富瑞在报告中称：\"基于此消息并保持审慎态度，我们现预计trofinetide在欧盟销售的版权收益将于2026财年第四季度初实现。得益于影像类产品的强劲需求，这家德国医疗企业的市场份额持续扩大。分析师补充道，该公司始终是板块重点推荐标的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LABU","XLV","BK4588","BK4581","XBI"],"gpt_icon":0},{"id":"2609651523","title":"Viemed Healthcare, Inc.盘中异动 股价大涨5.19%报8.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609651523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609651523?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 04:10","pubTimestamp":1770322215,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日04时10分，Viemed Healthcare, Inc.股票出现异动，股价急速拉升5.19%。Viemed Healthcare, Inc.股票所在的医疗器械行业中，整体涨幅为0.15%。其相关个股中，Trisalus Life Sciences Inc C/Wts 10/08/28 、Tenon Medical Inc C/Wts 16/06/2028 、Nexalin Technology, Inc.涨幅较大，Envue Medical, Inc.、Nexalin Technology, Inc.、Intelligent Bio Solutions Inc.较为活跃，换手率分别为221.64%、31.32%、18.00%，振幅较大的相关个股有Tela Bio, Inc.、Envue Medical, Inc.、Nuwellis, Inc.，振幅分别为60.01%、19.17%、18.27%。Viemed Healthcare, Inc.公司简介：Viemed Healthcare Inc 是一家为呼吸系统疾病、汲氧问题、睡眠呼吸暂停和 PAP 治疗患者提供医疗设备和家庭治疗的供应商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020604101595400892&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020604101595400892&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VMD","LABU","BK4196","XBI","XLV","BK4585","BK4581"],"gpt_icon":0},{"id":"2609884375","title":"爱普股份(603020.SH)签订关于挪亚圣诺(太仓)生物科技有限公司股权收购意向协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2609884375","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609884375?lang=zh_cn&edition=fundamental","pubTime":"2026-02-06 01:34","pubTimestamp":1770312881,"startTime":"0","endTime":"0","summary":"智通财经APP讯，爱普股份 发布公告，为完善公司战略布局，推动产业链的补强与延伸，实现公司高质量发展，2026年2月4日，公司与挪亚圣诺欧洲签订了《关于挪亚圣诺(太仓)生物科技有限公司之股权收购意向协议》，爱普股份拟受让挪亚圣诺(太仓)生物科技有限公司100% 股权，其中：首次交易即爱普股份受让目标公司80%股权，第二次交易于业绩承诺期满后启动，爱普股份将受让目标公司剩余股权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","603020","LABU","BK4585","159837","BK4588"],"gpt_icon":0},{"id":"2609588416","title":"Healthcare Triangle, Inc.盘中异动跌6.40% 换手率达47.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609588416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609588416?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 23:34","pubTimestamp":1770305648,"startTime":"0","endTime":"0","summary":"北京时间2026年02月05日23时34分，Healthcare Triangle, Inc.股票出现波动，股价急速跳水6.40%。Healthcare Triangle, Inc.股票所在的健康信息服务行业中，整体跌幅为1.74%。Healthcare Triangle, Inc.公司简介：Healthcare Triangle Inc 是一家专注于推动行业变革解决方案的医疗信息技术公司，主要关注云服务、数据科学以及医疗和生命科学行业的专业与托管服务领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020523340897a510bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020523340897a510bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["XBI","BK4588","BK4581","LABU","BK4167","BK4585","XLV","HCTI"],"gpt_icon":0},{"id":"2609737157","title":"瑞银——美国医疗保健服务行业周度观察（附下载）","url":"https://stock-news.laohu8.com/highlight/detail?id=2609737157","media":"外资精华观点","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609737157?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 15:42","pubTimestamp":1770277357,"startTime":"0","endTime":"0","summary":"免费体验“高时效”国际投行研报“T+0至T+1”“原研报”可至底部下载瑞银——美国医疗保健服务行业周度观察：医疗人员配置与急性期后护理板块表现突出，美国医疗支出增长，管理式医疗CEO将出席听证会精华翻译 板块表现分化：截至1月16日当周，医疗保健服务类股上涨0.6%，跑赢标普500指数及 broader医疗保健指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161612a47f4a2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205161612a47f4a2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0128526141.USD","HCSG","LU0029874061.USD","XBI","BK4585","XLV","BK4137","BK4581","LABU"],"gpt_icon":0},{"id":"2609321873","title":"AI生物科技公司Generate(GENB.US)拟赴美IPO募资1亿美元 核心哮喘疗法已进入III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321873","media":"智通财经网","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609321873?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 14:52","pubTimestamp":1770274343,"startTime":"0","endTime":"0","summary":"专注于哮喘治疗的AI生物科技公司Generate Biomedicines(GENB.US)周三向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多1亿美元。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205145238_12198.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401992.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LABU","BK4588","BK4134","BK4585","III","159837"],"gpt_icon":0},{"id":"2609347749","title":"诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2609347749","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609347749?lang=zh_cn&edition=fundamental","pubTime":"2026-02-05 13:49","pubTimestamp":1770270542,"startTime":"0","endTime":"0","summary":"【诺华在华去年收入42亿美元 CEO称中国正迅速成长为全球研发和生物科技中心】“毫无疑问，中国不仅已经成为像诺华这样的大型制药公司极为重要的市场，同时也正在迅速成长为一个全球性的研发与生物科技中心。”2月4日，诺华（NVS.US）首席执行官万思瀚在财报会上表达了上述观点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642639990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642639990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","LABU","LU0070302665.USD","IE00B2B36J28.USD","BK4532","IE00BFTCPJ56.SGD","LU0211331839.USD","IE0002141913.USD","LU0320765489.SGD","159837","BK4588","IE0009355771.USD","BK4007","BK4578","IE00B4R5TH58.HKD","NVS"],"gpt_icon":0},{"id":"2608138360","title":"生物科技公司PrimeGen将通过15亿美元SPAC交易上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2608138360","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608138360?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 22:16","pubTimestamp":1770214560,"startTime":"0","endTime":"0","summary":"生物科技公司 PrimeGen US 周三表示，将通过与空白支票公司 DT Cloud Star Acquisition 达成的15 亿美元交易，在美国实现上市。　　该交易预计于2026 年下半年完成。合并后的公司将以 PrimeGen US 名义运营，并计划在纳斯达克交易所挂牌上市。　　此次交易落地之际，企业对通过特殊目的收购公司合并实现上市的兴趣再度升温，将其作为传统上市方式的替代选择。　　PrimeGen 是一家专注于干细胞疗法研发的生物科技公司，主打针对急性肝损伤及相关重症的治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-04/doc-inhksktz9552911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","LABU","BK4585","159837"],"gpt_icon":0},{"id":"2608362077","title":"复星医药：公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2608362077","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608362077?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 21:37","pubTimestamp":1770212245,"startTime":"0","endTime":"0","summary":"证券日报网讯2月4日，复星医药在互动平台回答投资者提问时表示，公司自1994年创立于上海，是一家植根中国、创新驱动的全球化医药健康产业集团。目前，公司直接运营的业务覆盖制药、医疗器械及医学诊断、医疗健康服务；其中，制药是公司的核心主营业务，也是公司品牌建设的重要承载。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602043641720167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159883","BK0183","BK0188","02196","BK0196","BK1191","09997","BK1574","BK4588","BK4581","600196","09996","BK0175","BK0012","XBI","BK1593","BK0239","01477","BK0028","159760","LABU","BK0096","BK4585","BK0187","BK1222","BK1515","XLV","BK1100","BK0060","BK1583"],"gpt_icon":0},{"id":"2608334357","title":"一线｜脑机接口商业化转向：企业正加速从消费场景转向医疗健康领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2608334357","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608334357?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 18:08","pubTimestamp":1770199680,"startTime":"0","endTime":"0","summary":"随着研发与产业化的推进，脑机接口的商业化重心正明显向医疗健康领域集中。脑机接口设备日趋便携化、小型化，并在国内完善产业链的支撑下走向大规模量产。脑机接口领域在蓬勃发展的表象之下，亦潜藏着根本性的战略分歧。脑机接口行业从业人员李飞告诉蓝鲸科技记者。当脑机接口决定认真“治病”近年来，脑机接口企业正加速从消费场景转向医疗健康领域。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1770193931196031365","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["XLV","159760","BK4588","XBI","BK4581","LABU","BK4585"],"gpt_icon":0},{"id":"2608356276","title":"红日药业：公司业务布局可大致分为中药配方颗粒、成品药、医疗器械、原辅料、医疗健康服务和药械智慧供应链","url":"https://stock-news.laohu8.com/highlight/detail?id=2608356276","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608356276?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 16:29","pubTimestamp":1770193772,"startTime":"0","endTime":"0","summary":"证券之星消息，红日药业02月04日在投资者关系平台上答复投资者关心的问题。公司在巩固核心产品市场地位的同时，积极推动配方颗粒业务提质增效，以应对集采政策影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260204/31997911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["XBI","BK0188","159883","09996","BK1583","BK1574","BK4588","BK0077","BK4581","BK1100","BK4585","LABU","XLV","300026","09997","BK0239","159760","BK1222"],"gpt_icon":0},{"id":"2608386432","title":"创新链产业链无缝对接 推动产业整体跃升","url":"https://stock-news.laohu8.com/highlight/detail?id=2608386432","media":"无锡新传媒","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608386432?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 06:12","pubTimestamp":1770156720,"startTime":"0","endTime":"0","summary":"出席省两会的无锡代表委员们各抒己见、贡献良策，一致表示，要坚持把实体经济作为发展经济的着力点，以创新链和产业链的无缝对接推动产业体系整体跃升，让新时代工商名城城市品牌的国际知名度和美誉度明显提升；以经济大市挑大梁的高度责任感勇担时代使命，为全国全省发展大局作出更大贡献。为“双高协同”架桥 打通产学研融合之路省政协委员 匡华　　今年的省政府工作报告，把加力推动科技创新和产业创新融合列入年度重点工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-04/doc-inhkqwsx3917463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":161,"code":"91000000","status":"200"}]}}